发布求助
文献互助 智能选刊 最新文献

Current Hematologic Malignancy Reports最新文献

筛选
英文 中文
Pulmonary, Hepatic, and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Telomere Biology Disorders. 端粒生物学紊乱患者的肺、肝和异体造血干细胞移植。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-02-05 DOI: 10.1007/s11899-024-00724-z
Kelly M Pennington, Douglas Simonetto, Timucin Taner, Abhishek A Mangaonkar
{"title":"Pulmonary, Hepatic, and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Telomere Biology Disorders.","authors":"Kelly M Pennington, Douglas Simonetto, Timucin Taner, Abhishek A Mangaonkar","doi":"10.1007/s11899-024-00724-z","DOIUrl":"10.1007/s11899-024-00724-z","url":null,"abstract":"<p><strong>Purpose of the review: </strong>This study aimed to summarize evidence and provide consensus-based guidelines for management of transplantation in patients with telomere biology disorders (TBD). Specifically, this review focuses on clinical management of lung, liver, and bone marrow transplantation in TBD patients.</p><p><strong>Recent findings: </strong>TBD patients have specific unique biological vulnerabilities such as T cell immunodeficiency, susceptibility to infections, hypersensitivity to chemotherapy and radiation, and cytopenias. Furthermore, multiple organ involvement at diagnosis makes clinical management especially challenging due to higher degree of organ damage, and stress-induced telomeric crisis. Sequential and combined organ transplants, development of novel radiation and alkylator-free conditioning regimen, and use of novel drugs for graft-versus-host disease prophylaxis are some of the recent updates in the field. Multidisciplinary management is essential to optimize transplant outcomes in patients with TBD. In this review, we provide consensus-based transplant management guidelines for clinical management of transplant in TBD.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"293-299"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease. 预防和治疗移植物抗宿主病的当代最新进展。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-11-09 DOI: 10.1007/s11899-024-00741-y
Sameem Abedin, Mehdi Hamadani
{"title":"Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease.","authors":"Sameem Abedin, Mehdi Hamadani","doi":"10.1007/s11899-024-00741-y","DOIUrl":"10.1007/s11899-024-00741-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Graft-versus-host disease (GVHD) is a serious complication after allogeneic HCT. Recently, several pivotal studies have been conducted demonstrating significant improvements in the management of GVHD. Here, we review important trials pertaining to GVHD prevention, acute GVHD treatment, and treatment of steroid refractory acute and chronic GVHD.</p><p><strong>Recent findings: </strong>Clinical trials in preventing GVHD demonstrate lower rates of severe acute GVHD and chronic GVHD with post-transplant cyclophosphamide. For acute GVHD, lower risk acute GVHD appears amenable to steroid-sparing therapies, such as sirolimus and itacitinib. Combinations with novel agents such as itolizumab appear promising for high risk acute GVHD. For steroid-refractory acute GVHD, ruxolitinib should be considered first line therapy. For chronic GVHD requiring therapy beyond steroids, ruxolitinib, belumosudil, and ibrutinib are now available and should be considered. Increasingly, GVHD has become a manageable complication after allogeneic HCT potentially translating to greater success with allogeneic HCT in the future.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"19 6","pages":"246-255"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma. 多发性骨髓瘤中与 BCMA、GPRC5D 和 FcRH5 靶向双特异性抗体相关的毒性管理。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-08-15 DOI: 10.1007/s11899-024-00740-z
Darren Pan, Joshua Richter
{"title":"Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.","authors":"Darren Pan, Joshua Richter","doi":"10.1007/s11899-024-00740-z","DOIUrl":"10.1007/s11899-024-00740-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>The introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refractory multiple myeloma. This review will summarize the management of the toxicities associated with newly approved T cell-engaging bispecific antibodies and those which may be approved in the near future.</p><p><strong>Recent findings: </strong>Numerous trials have shown that bispecific antibodies can be both effective and tolerable when adverse events are properly managed. Cytokine release syndrome and increased infections are observed across all bispecific antibodies. Additional adverse events are target-specific, such as the more severe hypogammaglobulinemia and infections of BCMA bispecific antibodies and the dysgeusia, nail dystrophy, and skin changes of GPRC5D bispecific antibodies. Bispecific antibodies will surely become a mainstay of multiple myeloma therapy given their efficacy and accessibility. Their unique toxicities must be carefully considered and managed to ensure they are utilized safely.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"237-245"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in Stem Cell Transplantation for Myelofibrosis. 干细胞移植治疗骨髓纤维化的进展。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-09-06 DOI: 10.1007/s11899-024-00742-x
Akhil Rajendra, Vikas Gupta
{"title":"Advances in Stem Cell Transplantation for Myelofibrosis.","authors":"Akhil Rajendra, Vikas Gupta","doi":"10.1007/s11899-024-00742-x","DOIUrl":"10.1007/s11899-024-00742-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for myelofibrosis. This review discusses issues not well-covered by existing guidelines: timing of transplant, pre-transplant spleen management and alternative donors; providing our approach to these situations.</p><p><strong>Recent findings: </strong>Research continues to allow better identification, by better risk stratification and advances in understanding likelihood of durable JAKi response, which patients are likely to derive benefit from upfront transplant versus those for whom delayed transplant may be more appropriate. Several options of JAKi therapy provide a non-surgical option for pre-HCT splenomegaly management, allowing some patients to avoid risks associated with splenectomy. Recent years have also seen a sharp spike in haploidentical donor transplants, along with narrowing of the gap in outcomes between donor types. Continuous enrollment in prospective studies or well-designed registries is required to generate the high-quality data needed to develop better decision tools for these scenarios.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"256-263"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas. T 细胞淋巴瘤患者干细胞移植后的维持疗法。
IF 4.6 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-10-19 DOI: 10.1007/s11899-024-00743-w
Zachary Braunstein, Jonathan E Brammer
{"title":"Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas.","authors":"Zachary Braunstein, Jonathan E Brammer","doi":"10.1007/s11899-024-00743-w","DOIUrl":"10.1007/s11899-024-00743-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is increasingly being utilized. Here we review the use of post-SCT maintenance therapy for PTCL patients.</p><p><strong>Recent findings: </strong>Maintenance therapy is increasingly utilized to decrease post-SCT relapse and improve outcomes in PTCL. Ongoing and completed post-SCT maintenance trials utilizing agents such as romidepsin, brentuximab vedotin, duvelisib, and pembrolizumab have shown efficacy in decreasing relapse. Further, additional agents with efficacy in PTCL have emerged that may inform future maintenance approaches. Maintenance therapy is a promising approach to maintain response after SCT in PTCL. While several trials are ongoing to evaluate maintenance therapy in PTCL, current data suggests this may be an effective method to decrease post-SCT relapse.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"276-284"},"PeriodicalIF":4.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAK Inhibitors for Myelofibrosis: Strengths and Limitations. 治疗骨髓纤维化的 JAK 抑制剂：优势与局限。
IF 4.6 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-10-14 DOI: 10.1007/s11899-024-00744-9
K Thaw, C N Harrison, P Sriskandarajah
{"title":"JAK Inhibitors for Myelofibrosis: Strengths and Limitations.","authors":"K Thaw, C N Harrison, P Sriskandarajah","doi":"10.1007/s11899-024-00744-9","DOIUrl":"10.1007/s11899-024-00744-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development of JAK inhibitors (JAKis). However, treatment with JAKis remain a challenge. In this review we critically analyze the strengths and limitations of currently available JAK inhibitors.</p><p><strong>Recent findings: </strong>In MF patients, JAK inhibitors have been associated with reduced symptom burden and spleen size, as well as improved survival. However, durability of response and development of treatment resistance remain an issue. Recently, there has been increased efforts to optimize treatment with the development of highly selective JAK inhibitors, as well as use of combination agents to counter disease resistance through targeting aberrant signaling pathways. Treatment of MF patients with JAKi therapy can be challenging but the development of more potent and selective JAK inhibitors, as well as combination therapies, represent exciting treatment advances in this field.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"264-275"},"PeriodicalIF":4.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic Mastocytosis: State of the Art. 系统性肥大细胞增多症：艺术现状。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-10-01 Epub Date: 2024-08-27 DOI: 10.1007/s11899-024-00737-8
Isabel Farmer, Deepti H Radia
{"title":"Systemic Mastocytosis: State of the Art.","authors":"Isabel Farmer, Deepti H Radia","doi":"10.1007/s11899-024-00737-8","DOIUrl":"10.1007/s11899-024-00737-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), there has been a wealth of new research in therapeutic targeting of the pathogenic C-KIT D816V mutation.</p><p><strong>Recent findings: </strong>Avapritinib, the first licensed drug in SM capable of disease modification alongside the increasingly potent, oral and highly selective KIT tyrosine kinase inhibitors (TKIs) Bezuclastinib and now Elenestinib have enabled the prospect of long-term remissions. Studies have shown improved survival and symptomatic control in patients with SM. Of great triumph, this has been achieved in an outpatient setting with apparent tolerable and minimal toxicity. The importance of molecular profiling is being demonstrated in administering combination therapies for SM with an associated haematological neoplasm (AHN), allowing more personalised and streamlined treatment regimes. This review focuses on current management strategies of SM, focusing on state-of-the-art directed therapies, the evidence behind their use with presentation of two clinical cases to highlight key messages.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"197-207"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals. 在酪氨酸激酶抑制剂和生物制剂时代，如何治疗嗜酸性粒细胞增多症患者？
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-10-01 Epub Date: 2024-07-22 DOI: 10.1007/s11899-024-00738-7
Johannes Lübke, Georgia Metzgeroth, Andreas Reiter, Juliana Schwaab
{"title":"Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals.","authors":"Johannes Lübke, Georgia Metzgeroth, Andreas Reiter, Juliana Schwaab","doi":"10.1007/s11899-024-00738-7","DOIUrl":"10.1007/s11899-024-00738-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, we aim to explore the optimal approach to patients presenting with eosinophilia, considering recent advances in diagnostic and therapeutic strategies. Specifically, we focus on the integration of novel therapies into clinical practice to improve patient outcomes.</p><p><strong>Recent findings: </strong>Advanced insights into the clinical and genetic features of eosinophilic disorders have prompted revisions in diagnostic criteria by the World Health Organization classification (WHO-HAEM5) and the International Consensus Classification (ICC). These changes reflect a growing understanding of disease pathogenesis and the development of targeted treatment options. The therapeutic landscape now encompasses a range of established and novel therapies. For reactive conditions, drugs targeting the eosinophilopoiesis, such as those aimed at interleukin-5 or its receptor, have demonstrated significant potential in decreasing blood eosinophil levels and minimizing disease flare-ups and relapse. These therapies have the potential to mitigate the side effects commonly associated with prolonged use of oral corticosteroids or immunosuppressants. Myeloid and lymphoid neoplasms with eosinophilia and tyrosine kinase (TK) gene fusions are managed by various TK inhibitors with variable efficacy. Diagnosis and treatment rely on a multidisciplinary approach. By incorporating novel treatment options into clinical practice, physicians across different disciplines involved in the management of eosinophilic disorders can offer more personalized and effective care to patients. However, challenges remain in accurately diagnosing and risk-stratifying patients, as well as in navigating the complexities of treatment selection.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"208-222"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic and Predictive Models in Myelofibrosis. 骨髓纤维化的预后和预测模型
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-10-01 Epub Date: 2024-08-24 DOI: 10.1007/s11899-024-00739-6
Barbara Mora, Cristina Bucelli, Daniele Cattaneo, Valentina Bellani, Francesco Versino, Kordelia Barbullushi, Nicola Fracchiolla, Alessandra Iurlo, Francesco Passamonti
{"title":"Prognostic and Predictive Models in Myelofibrosis.","authors":"Barbara Mora, Cristina Bucelli, Daniele Cattaneo, Valentina Bellani, Francesco Versino, Kordelia Barbullushi, Nicola Fracchiolla, Alessandra Iurlo, Francesco Passamonti","doi":"10.1007/s11899-024-00739-6","DOIUrl":"10.1007/s11899-024-00739-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven and nine years, respectively. Main causes of mortality are non-clonal progression and transformation into blast phase.</p><p><strong>Recent findings: </strong>Discoveries on the impact of the biological architecture on OS have led to the design of integrated scores to predict survival in PMF. For SMF, OS estimates should be calculated by the specific MYSEC-PM (MYelofibrosis SECondary-prognostic model). Information on the prognostic role of the molecular landscape in SMF is accumulating. Crucial treatment decisions for MF patients could be now supported by multivariable predictive algorithms. OS should become a relevant endpoint of clinical trials. Prognostic models guide prediction of OS and treatment planning in MF, therefore, their timely application is critical in the personalized approach of MF patients.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"223-235"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications. 费城染色体阳性 ALL 的 MRD：方法和临床意义。
IF 2.7 3区 医学
Current Hematologic Malignancy Reports Pub Date : 2024-08-01 Epub Date: 2024-06-18 DOI: 10.1007/s11899-024-00736-9
Valerie Tran, Kiarash Salafian, Kenan Michaels, Caroline Jones, Daniel Reed, Michael Keng, Firas El Chaer
{"title":"MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.","authors":"Valerie Tran, Kiarash Salafian, Kenan Michaels, Caroline Jones, Daniel Reed, Michael Keng, Firas El Chaer","doi":"10.1007/s11899-024-00736-9","DOIUrl":"10.1007/s11899-024-00736-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Measurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate MRD as well as the interpretation, significance, and incorporation of MRD in current practice.</p><p><strong>Recent findings: </strong>New molecular technologies have allowed the detection of MRD to levels as low as 10<sup>- 6</sup>. The most used techniques to evaluate MRD are multiparametric flow cytometry (MFC), quantitative reverse transcription polymerase chain reaction (RT-qPCR), and high-throughput next-generation sequencing (NGS). Each method varies in terms of advantages, disadvantages, and MRD sensitivity. MRD negativity after induction treatment and after allogeneic hematopoietic cell transplantation (HCT) is an important prognostic marker that has consistently been shown to be associated with improved outcomes. Blinatumomab, a new targeted therapy for Ph + ALL, demonstrates high efficacy in eradicating MRD and improving patient outcomes. In the relapsed/refractory setting, the use of inotuzumab ozogamicin and tisagenlecleucel has shown promise in eradicating MRD. The presence of MRD has become an important predictive measure in Ph + ALL. Current studies evaluate the use of MRD in treatment decisions, especially in expanding therapeutic options for Ph + ALL, including tyrosine kinase inhibitors, targeted antibody therapies, chimeric antigen receptor cell therapy, and HCT.</p>","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"186-196"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信